Bank of Nova Scotia Purchases 19,660 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bank of Nova Scotia grew its stake in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 68.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 48,242 shares of the medical equipment provider’s stock after acquiring an additional 19,660 shares during the quarter. Bank of Nova Scotia’s holdings in Hologic were worth $3,447,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Deseret Mutual Benefit Administrators lifted its position in shares of Hologic by 42.2% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 155 shares during the period. Arizona State Retirement System lifted its position in shares of Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after acquiring an additional 172 shares during the period. Lincoln National Corp lifted its position in shares of Hologic by 4.0% during the 4th quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after acquiring an additional 178 shares during the period. Allworth Financial LP lifted its position in shares of Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares during the period. Finally, Great Lakes Retirement Inc. lifted its position in shares of Hologic by 1.6% during the 4th quarter. Great Lakes Retirement Inc. now owns 11,859 shares of the medical equipment provider’s stock valued at $847,000 after acquiring an additional 186 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insider Transactions at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on HOLX. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Needham & Company LLC restated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. Evercore ISI upped their price objective on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. JPMorgan Chase & Co. upped their price objective on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Finally, Argus upped their price objective on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $85.60.

Check Out Our Latest Analysis on Hologic

Hologic Price Performance

Hologic stock opened at $74.25 on Thursday. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $17.33 billion, a PE ratio of 37.88, a P/E/G ratio of 2.49 and a beta of 1.00. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $82.45. The stock has a 50-day moving average price of $75.79 and a two-hundred day moving average price of $74.04.

Hologic (NASDAQ:HOLXGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $1.06 earnings per share. The firm’s revenue was down .8% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.08 EPS for the current year.

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.